Berenberg Bank Reiterates Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZNGet Free Report)‘s stock had its “buy” rating reaffirmed by Berenberg Bank in a report issued on Tuesday,Digital Look reports. They presently have a £160 target price on the biopharmaceutical company’s stock. Berenberg Bank’s price objective points to a potential upside of 25.39% from the stock’s previous close.

Several other analysts have also recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 price objective on shares of AstraZeneca in a research report on Friday, June 26th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th. Finally, Citigroup lowered AstraZeneca to a “buy” rating in a research report on Friday, July 10th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of £153.

Get Our Latest Analysis on AstraZeneca

AstraZeneca Price Performance

Shares of LON AZN opened at £127.60 on Tuesday. AstraZeneca has a 1 year low of £107.44 and a 1 year high of £157.32. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The company’s 50-day moving average is £134.89 and its 200 day moving average is £140.60. The stock has a market capitalization of £197.89 billion, a P/E ratio of 19.22, a P/E/G ratio of 0.86 and a beta of 0.23.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Further Reading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.